Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.40 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | RGS12 | O14924 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27545640 | 0.86 | GAA (0.42) | KDM4CPPARATAS2R14STING1ALDH1A1 | |
| SCHEMBL580229 | 0.86 | PPARA (0.55) | KDM4CPPARASTING1ALDH1A1MAPT | |
| SCHEMBL580270 | 0.85 | KDM4E (0.47) | KDM4CPPARASTING1ALDH1A1MAPT | |
| SCHEMBL3996778 | 0.85 | PPARA (0.54) | KDM4CPPARASTING1ALDH1A1MAPT | |
| SCHEMBL3996092 | 0.85 | PPARA (0.54) | KDM4CPPARASTING1ALDH1A1MAPT | |
| SCHEMBL3996747 | 0.85 | PPARA (0.54) | KDM4CPPARASTING1ALDH1A1MAPT | |
| Potassium SCHEMBL29515374 | 0.85 | PPARA (0.54) | KDM4CPPARASTING1ALDH1A1MAPT | |
| SCHEMBL581497 | 0.85 | PPARA (0.40) | KDM4CPPARATAS2R14STING1ALDH1A1 | |
| SCHEMBL580201 | 0.84 | EPHX2 (0.40) | KDM4CPPARATAS2R14STING1ALDH1A1 | |
| SCHEMBL580279 | 0.84 | EGFR (0.43) | KDM4CPPARASTING1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027076-A1 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | GNT PHARMA CO LTD (KR) | 2026-01-29 | — | — | US | claimed |
| US-12433861-B2 | Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy | GNT PHARMA CO., LTD. (KR) | 2025-10-07 | — | — | US | claimed |
| US-20230390231-A1 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | GNT PHARMA CO., LTD. (KR) | 2023-12-07 | — | — | US | claimed |
| US-11826329-B2 | Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy | GNT PHARMA CO., LTD. (KR) | 2023-11-28 | — | — | US | claimed |
| EP-4117648-A1 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | GNT Pharma Co., Ltd (KR) | 2023-01-18 | — | — | EP | claimed |
| CN-115515573-A | Compositions and methods for treating reperfusion injury or bleeding following recanalization | GNT制药有限公司 | 2022-12-23 | — | — | CN | claimed |
| US-20210283080-A1 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | GNT PHARMA CO., LTD. (KR) | 2021-09-16 | — | — | US | claimed |
| WO-2021181159-A1 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | GNT PHARMA CO., LTD. (KR) | 2021-09-16 | — | — | WO | claimed |
| EP-2417972-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING BURN INJURIES | NEUROTECH PHARMACEUTICALS CO LTD (KR) | 2017-06-14 | — | — | EP | claimed |
| EP-1551793-B1 | TETRAFLUOROBENZYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES IN CENTRAL NERVOUS SYSTEM CONTAINING THE SAME | AMKOR PHARMA INC (US) | 2016-01-20 | — | — | EP | claimed |
| US-20070298129-A1 | Compounds and compositions for treating neuronal death or neurological dysfunction | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2007-12-27 | — | — | US | claimed |
| CN-1309703-C | Tetrafluorobenzyl derivatives and pharmaceutical composition for treating and preventing acute and chronic neurodegenerative diseases of central nervous system containing the same | NEUROTECH CO LTD (KR) | 2007-04-11 | — | — | CN | claimed |
| EP-1551793-A4 | TETRAFLUOROBENZYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES IN CENTRAL NERVOUS SYSTEM CONTAINING THE SAME | NEUROTECH CO LTD (KR) | 2007-04-04 | — | — | EP | claimed |
| US-20070049565-A1 | Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2007-03-01 | — | — | US | claimed |
| WO-2006126825-A1 | COMPOSITION COMPRISING TETRAFLUOROBENZYL DERIVATIVES OR SALTS OF THEREOF FOR INJECTION | CHOONGWAE PHARMA CORPORATION (KR) | 2006-11-30 | — | — | WO | claimed |
| CN-1668576-A | Tetrafluorobenzyl derivatives and pharmaceutical composition for treating and preventing acute and chronic neurodegenerative diseases of central nervous system containing the same | NEUROTECH CO LTD (KR) | 2005-09-14 | — | — | CN | claimed |
| US-6927303-B2 | Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same | NEUROTECH CO., LTD. (KR) | 2005-08-09 | — | — | US | claimed |
| EP-1551793-A1 | TETRAFLUOROBENZYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES IN CENTRAL NERVOUS SYSTEM CONTAINING THE SAME | Neurotech Co., Ltd. (KR) | 2005-07-13 | — | — | EP | claimed |
| US-20040209957-A1 | Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2004-10-21 | — | — | US | claimed |
| WO-2004000786-A1 | TETRAFLUOROBENZYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES IN CENTRAL NERVOUS SYSTEM CONTAINING THE SAME | NEUROTECH CO., LTD. (KR) | 2003-12-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433861-B2 | Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy | PLAT, SERPINE1, SERPINC1 | KDM4C 4752/4885PPARA 3027/4885TAS2R14 455/4885 |
| US-11826329-B2 | Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy | PLAT, SERPINE1, SERPINC1 | KDM4C 4752/4885PPARA 3027/4885TAS2R14 455/4885 |
| US-20230390231-A1 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | PLAT, SERPINE1, SERPINC1 | KDM4C 4752/4885PPARA 3027/4885TAS2R14 455/4885 |
| US-20210283080-A1 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | PLAT, SERPINE1, SERPINC1 | KDM4C 4752/4885PPARA 3027/4885TAS2R14 455/4885 |
| US-20070298129-A1 | Compounds and compositions for treating neuronal death or neurological dysfunction | BCL2, BAX, SMN1; SMN2 | KDM4C 3544/4885PPARA 1265/4885TAS2R14 3628/4885 |
| US-20260027076-A1 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | FGB, PLAT, CTSH | KDM4C 3647/4885PPARA 348/4885TAS2R14 363/4885 |
| US-20070049565-A1 | Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction | BAD, MAP1LC3B, XIAP | KDM4C 4402/4885PPARA 4072/4885TAS2R14 3610/4885 |
| US-20040209957-A1 | Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same | HTT, BDNF, APP | KDM4C 3272/4885PPARA 289/4885TAS2R14 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.